NCT06965452 Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy
| NCT ID | NCT06965452 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwell Health |
| Condition | Facet Joint Arthropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-08-12 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-08-12 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
Eligibility Criteria
Inclusion Criteria: * Age 18-85 * Confirmed diagnosis of spinal facet arthropathy on MRI OR CT * Confirmed diagnosis of lumbosacral facetogenic pain based on diagnostic nerve blocks. * Failed medical management of pain. * Back pain persistent for at least 6 months * Pain worse than at least 6/10 on a visual analog pain scale * Failed at least one of either intra-articular injections of steroids/ anesthetics or neuro-ablative procedure. * Maximum of 2 spinal levels of facetogenic pain in the lumbar and sacral spine (i.e. L4-5 and L5-S1). * Modified Rankin Scale 0-2 Exclusion Criteria: * \- Pregnancy * History of prior spinal embolization at the target level. * History of surgery/ stenting of the aorta at the level of embolization. * Severe allergic reaction to iodinated contrast (i.e. anaphylaxis) * Creatinine \> 1.5 mg/dl and/or creatinine clearance \< 60 mL/min (except if patients is already on hemodialysis). * Modified Rankin Scale \>2 * Angiographic/ Procedural Exclusion Criterion: Vascular supply to the spinal cord from the vessels supplying the facet joints targeted for embolization.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06965452 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Facet Joint Arthropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06965452 currently recruiting?
Yes, NCT06965452 is actively recruiting participants. Contact the research team at bmoclair@northwell.edu for enrollment information.
Where is the NCT06965452 trial being conducted?
This trial is being conducted at Manhasset, United States.
Who is sponsoring the NCT06965452 clinical trial?
NCT06965452 is sponsored by Northwell Health. The trial plans to enroll 40 participants.